1-3 of 3
Eric K. Rowinsky, MD
Close
Sort by
Journal Articles

SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity

Janice Chen, PhD, Christopher L. Brooks, PhD, Peter McDonald, Jonathan D. Schwartz, MD, Rebecca S. Schneider, Keiichi Sakakibara, PhD, Naoya Saito, PhD, Takuji Sato, MSc, Takumi Kawabe, MD PhD, Eric K. Rowinsky, MD
Journal: Blood
Blood (2015) 126 (23): 4433.
https://doi.org/10.1182/blood.V126.23.4433.4433
Published: 2015
Journal Articles

Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)

Kendra L. Sweet, MD, Naveen Pemmaraju, MD, Andrew A Lane, MD PhD, Anthony S. Stein, MD, Sumithira Vasu, MBBS, William Blum, MD, David A. Rizzieri, MD, Eunice S. Wang, MD, Eric K. Rowinsky, MD, Michael Szarek, PhD, Christopher L. Brooks, PhD, Sarah Disalvatore, MPH, David Liu, Madeleine Duvic, MD, Jonathan D. Schwartz, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2015) 126 (23): 3795.
https://doi.org/10.1182/blood.V126.23.3795.3795
Published: 2015
Journal Articles

A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism

Arghya Ray, PhD, Deepika Sharma DAS, PhD, Yan Song, PhD, Vincent Macri, MA, Christopher L. Brooks, PhD, Eric K. Rowinsky, MD, Paul G. Richardson, MD, Dharminder Chauhan, PhD, Kenneth C Anderson, MD
Journal: Blood
Blood (2015) 126 (23): 3000.
https://doi.org/10.1182/blood.V126.23.3000.3000
Published: 2015